J&J Plans €1.75B Offer For Dutch Vaccine Developer
By Melissa Lipman ( September 20, 2010, 11:42 AM EDT) -- Johnson & Johnson is in advanced talks to buy the bulk of vaccine developer Crucell NV for €1.75 billion ($2.29 billion) through an all-cash public offer that would give the U.S. pharmaceutical giant full control over the Dutch company....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.